vs
Side-by-side financial comparison of DYNAVAX TECHNOLOGIES CORP (DVAX) and READING INTERNATIONAL INC (RDI). Click either name above to swap in a different company.
DYNAVAX TECHNOLOGIES CORP is the larger business by last-quarter revenue ($94.9M vs $50.3M, roughly 1.9× READING INTERNATIONAL INC). DYNAVAX TECHNOLOGIES CORP runs the higher net margin — 28.4% vs -5.1%, a 33.5% gap on every dollar of revenue. On growth, DYNAVAX TECHNOLOGIES CORP posted the faster year-over-year revenue change (17.7% vs -14.2%). DYNAVAX TECHNOLOGIES CORP produced more free cash flow last quarter ($32.6M vs $4.1M). Over the past eight quarters, DYNAVAX TECHNOLOGIES CORP's revenue compounded faster (30.6% CAGR vs 5.6%).
Dynavax Technologies Corp is a commercial-stage biopharmaceutical company specializing in the research, development, and production of innovative vaccines and immunotherapies for infectious diseases. Its lead approved product is Heplisav-B, an adult hepatitis B vaccine, with core markets in North America and Europe, alongside a pipeline of candidates addressing unmet public health needs.
The Reading Company was a Philadelphia-headquartered railroad that provided passenger and freight transport in eastern Pennsylvania and neighboring states from 1924 until its acquisition by Conrail in 1976.
DVAX vs RDI — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $94.9M | $50.3M |
| Net Profit | $26.9M | $-2.6M |
| Gross Margin | — | — |
| Operating Margin | 22.4% | -1.9% |
| Net Margin | 28.4% | -5.1% |
| Revenue YoY | 17.7% | -14.2% |
| Net Profit YoY | 53.0% | -14.5% |
| EPS (diluted) | $0.21 | $-0.11 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $50.3M | ||
| Q3 25 | $94.9M | $52.2M | ||
| Q2 25 | $95.4M | $60.4M | ||
| Q1 25 | $68.2M | $40.2M | ||
| Q4 24 | $72.0M | $58.6M | ||
| Q3 24 | $80.6M | $60.1M | ||
| Q2 24 | $73.8M | $46.8M | ||
| Q1 24 | $50.8M | $45.1M |
| Q4 25 | — | $-2.6M | ||
| Q3 25 | $26.9M | $-4.2M | ||
| Q2 25 | $18.7M | $-2.7M | ||
| Q1 25 | $-96.1M | $-4.8M | ||
| Q4 24 | $7.0M | $-2.2M | ||
| Q3 24 | $17.6M | $-7.0M | ||
| Q2 24 | $11.4M | $-12.8M | ||
| Q1 24 | $-8.7M | $-13.2M |
| Q4 25 | — | -1.9% | ||
| Q3 25 | 22.4% | -0.6% | ||
| Q2 25 | 15.1% | 4.8% | ||
| Q1 25 | -34.7% | -17.2% | ||
| Q4 24 | -2.3% | 2.6% | ||
| Q3 24 | 12.5% | -0.6% | ||
| Q2 24 | 7.0% | -16.4% | ||
| Q1 24 | -35.0% | -16.7% |
| Q4 25 | — | -5.1% | ||
| Q3 25 | 28.4% | -8.0% | ||
| Q2 25 | 19.6% | -4.4% | ||
| Q1 25 | -141.0% | -11.8% | ||
| Q4 24 | 9.8% | -3.8% | ||
| Q3 24 | 21.8% | -11.7% | ||
| Q2 24 | 15.4% | -27.4% | ||
| Q1 24 | -17.2% | -29.4% |
| Q4 25 | — | $-0.11 | ||
| Q3 25 | $0.21 | $-0.18 | ||
| Q2 25 | $0.14 | $-0.12 | ||
| Q1 25 | $-0.77 | $-0.21 | ||
| Q4 24 | $0.07 | $-0.11 | ||
| Q3 24 | $0.12 | $-0.31 | ||
| Q2 24 | $0.08 | $-0.57 | ||
| Q1 24 | $-0.07 | $-0.59 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $160.2M | $10.5M |
| Total DebtLower is stronger | — | $185.1M |
| Stockholders' EquityBook value | $534.1M | $-18.2M |
| Total Assets | $946.5M | $434.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $10.5M | ||
| Q3 25 | $160.2M | $8.1M | ||
| Q2 25 | $99.1M | $9.1M | ||
| Q1 25 | $51.7M | $5.9M | ||
| Q4 24 | $95.9M | $12.4M | ||
| Q3 24 | $119.3M | $10.1M | ||
| Q2 24 | $112.5M | $9.3M | ||
| Q1 24 | $132.0M | $7.5M |
| Q4 25 | — | $185.1M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $202.7M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | $-18.2M | ||
| Q3 25 | $534.1M | $-12.1M | ||
| Q2 25 | $494.2M | $-7.7M | ||
| Q1 25 | $530.9M | $-8.1M | ||
| Q4 24 | $596.8M | $-4.4M | ||
| Q3 24 | $681.4M | $1.6M | ||
| Q2 24 | $642.8M | $6.5M | ||
| Q1 24 | $618.5M | $18.0M |
| Q4 25 | — | $434.9M | ||
| Q3 25 | $946.5M | $435.2M | ||
| Q2 25 | $918.4M | $438.1M | ||
| Q1 25 | $945.9M | $441.0M | ||
| Q4 24 | $986.3M | $471.0M | ||
| Q3 24 | $1.1B | $495.7M | ||
| Q2 24 | $1.0B | $494.9M | ||
| Q1 24 | $986.6M | $494.9M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $33.8M | $4.3M |
| Free Cash FlowOCF − Capex | $32.6M | $4.1M |
| FCF MarginFCF / Revenue | 34.4% | 8.2% |
| Capex IntensityCapex / Revenue | 1.3% | 0.3% |
| Cash ConversionOCF / Net Profit | 1.26× | — |
| TTM Free Cash FlowTrailing 4 quarters | $80.5M | $-2.9M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $4.3M | ||
| Q3 25 | $33.8M | $295.0K | ||
| Q2 25 | $23.4M | $1.6M | ||
| Q1 25 | $-19.6M | $-7.7M | ||
| Q4 24 | $53.0M | $8.0M | ||
| Q3 24 | $19.5M | $1.3M | ||
| Q2 24 | $10.7M | $-10.4M | ||
| Q1 24 | $-16.7M | $-2.8M |
| Q4 25 | — | $4.1M | ||
| Q3 25 | $32.6M | $-246.0K | ||
| Q2 25 | $22.0M | $1.2M | ||
| Q1 25 | $-23.6M | $-8.0M | ||
| Q4 24 | $49.5M | $7.0M | ||
| Q3 24 | $18.1M | $-1.1M | ||
| Q2 24 | $9.9M | $-10.6M | ||
| Q1 24 | $-17.4M | $-4.7M |
| Q4 25 | — | 8.2% | ||
| Q3 25 | 34.4% | -0.5% | ||
| Q2 25 | 23.0% | 1.9% | ||
| Q1 25 | -34.6% | -19.8% | ||
| Q4 24 | 68.8% | 12.0% | ||
| Q3 24 | 22.5% | -1.8% | ||
| Q2 24 | 13.5% | -22.7% | ||
| Q1 24 | -34.3% | -10.4% |
| Q4 25 | — | 0.3% | ||
| Q3 25 | 1.3% | 1.0% | ||
| Q2 25 | 1.5% | 0.6% | ||
| Q1 25 | 5.8% | 0.6% | ||
| Q4 24 | 4.8% | 1.7% | ||
| Q3 24 | 1.7% | 4.0% | ||
| Q2 24 | 1.1% | 0.5% | ||
| Q1 24 | 1.5% | 4.3% |
| Q4 25 | — | — | ||
| Q3 25 | 1.26× | — | ||
| Q2 25 | 1.25× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 7.52× | — | ||
| Q3 24 | 1.11× | — | ||
| Q2 24 | 0.94× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
DVAX
| HEPLISAVB | $90.0M | 95% |
| US Department Of Defense | $4.7M | 5% |
RDI
| Cinema Exhibition Segment | $46.9M | 93% |
| Real Estate Revenue | $3.4M | 7% |
